Precision Optics Corporation, Inc. Common stock logo

Precision Optics Corporation, Inc. Common stock(POCI)

upturn advisory logo
EXPLORE ADVISORIES AND THEIR HISTORY
QUALITY SIGNAL RECENCY
1-STAR RATING
Consider higher Upturn Star rating
BUY for 7 days
PROFIT SINCE LAST BUY
+5.66% ▲
LAST CLOSE
$5.23
11/13/2026
(24-hour delay)

Advisory History & Simulated Performance *

*as per simulation (see disclosures)
  • ALL
  • 1Y
  • 1M
  • 1W
  • BUY Advisory
  • SELL Advisory (Profit)
  • SELL Advisory (Loss)
  • Profit
  • Loss
  • PASS (Skip)
Upturn Stock price based on last close iconStock price based on last close
Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Advisory Performance History (Simulated)Advisory Performance History info

Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Upturn Advisory & Investor View for POCI

11/13/2026: POCI (1-star) has a low Upturn Star Rating. Not recommended to BUY.

Precision Optics Corporation, Inc. is a specialized manufacturer focused on high-precision micro-optics for medical devices and defense systems. Its primary strength lies in its deep engineering expertise, which allows it to serve as a valued partner to medical OEMs. The company's growth story is centered on the increasing demand for high-resolution imaging in minimally invasive surgical procedures. However, investors must consider significant risks, including its small market size, customer concentration, and the high competition in medical device manufacturing. This stock may suit investors looking for niche medical technology exposure, provided they monitor key OEM project wins and manufacturing efficiency closely.

How to Read the Upturn Advisory

The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.

Company fundamentals, valuation, risks, and news provide supporting context about the business.

Investor Fit

Investor styleFitWhy
Growth investorMixed fitThe company offers potential upside from the medical imaging trend but remains constrained by its small size and lumpy revenue.
Momentum investorWeak fitThe stock often experiences low liquidity and extended periods of consolidation rather than sustained price momentum.
Value investorMixed fitValuation is often tied to speculative growth rather than consistent earnings, making it a challenging fit for traditional value screens.
Dividend investorWeak fitThe company does not pay a dividend and focuses on reinvesting cash flow into operations.
Low-risk investorWeak fitHigh sensitivity to customer concentration and small-cap volatility makes this unsuitable for low-risk portfolios.

Risk Profile

Risk factorLevelWhy it matters
Price volatilityHighThe stock is subject to significant price swings due to low trading volume and sensitivity to single-contract outcomes.
Valuation riskMediumMarket expectations for growth can quickly fluctuate based on project updates or delays.
Competition risk (Medical Device/Optical)Medium / highLarger players possess greater scale and R&D budgets to potentially displace specialized solutions.
Business qualityMediumThe company maintains high-quality engineering standards but faces challenges in scaling operations profitably.
Dividend incomeLow / noneIncome-focused investors will find no yield to offset capital volatility.
Execution riskMedium / highSuccess relies heavily on meeting strict OEM timelines and technical specifications for medical device launches.

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 57.50M USD
Price to earnings Ratio -
1Y Target Price 8
Price to earnings Ratio -
1Y Target Price 8
Volume (30-day avg) 22.0K shares
Beta 0.23
52 Weeks Range 3.55 - 6.15
Updated Date 11/14/2026
52 Weeks Range 3.55 - 6.15
Updated Date 11/14/2026
Dividends yield (FY) -
Basic EPS (TTM) -0.43

Sector & Industry Intelligence

Sector

Healthcare

Bullish
Sentiment
Strong Bullish
Momentum
Momentum Steady
BUY participation
62.6%
Active BUY / eligible
72 / 115
30-Day BUY Count Change
+35
Market state
Strong Bullish

The number of qualifying BUY stocks has remained relatively stable.

Industry

Medical Instruments & Supplies

BUY participation
60.0%
Active BUY / eligible
3 / 5
30-Day BUY Count Change
+1

Eligible universe: 5 stocks.

Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.

Price Behavior

Flat / Range-Bound
PRICE PATH

Flat / Range-Bound

The stock price has been trading within a narrow range with minimal directional movement.

Moderately Choppy
PRICE STABILITY

Moderately Choppy

The stock has experienced noticeable price swings while retaining some directional structure.

Analysis of Past Performance

Type Stock
Historic Profit -37.77%
Avg. Invested days 32
Today’s Advisory Consider higher Upturn Star rating
Upturn Advisory Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance icon 2.0
Stock Returns Performance Upturn Returns Performance icon 1.0
Upturn Profits based on simulation icon Profits based on simulation
Upturn last close icon Last Close 11/13/2026

Upturn Scorecard

Upturn Star Rating

★★★★★
POCI receives a 3-star rating, supported by solid company fundamentals, and solid analyst coverage. The rating is constrained by weak unit economics, and weak price momentum.

Company Fundamentals

★★★★★
POCI has solid overall fundamentals (4 stars), with soft financial health, solid growth momentum, and solid ownership. In FY2026 versus FY2025, strong earnings growth (+37.2%) and strong revenue growth (+65.2%) are partially offset by weak cash generation (FCF margin -6.3%), weak profitability (net margin -11.5%).

Financial Health Rating

★★★★★
POCI's financial health is soft, with the relatively strongest area being solid liquidity, including working-capital and asset support (WC/assets 34.9%). Profitability is weak (1 stars), which helps explain the 2-star overall score.

Growth Momentum Score

★★★★★
Revenue growth is POCI's strongest growth driver at +65.2% FY2026 versus FY2025 (strong, 5 stars). Earnings growth (+37.2%, strong) and free-cash-flow growth (+47.6%, strong) are also constructive, though not equally high across every growth measure.

Ownership

★★★★★
Institutional ownership is 39.8% and approximately 75.1% of outstanding shares are publicly tradable, supporting liquidity and institutional participation. Insider ownership of 19.57% supports management-shareholder alignment.

Top 5 Institutional Investors

Needham Investment Management, LLC 15.22%
Nantahala Capital Management, LLC 5.10%
MYDA Advisors LLC 3.42%
Vanguard Capital Management, LLC 2.97%
WEALTHTRUST AXIOM LLC 2.37%

Unit Economics (Per $1K Revenue)

★★★★★
POCI generates approximately $172 of gross profit, $-111 of operating income, and $-63 of free cash flow for every $1,000 of revenue. Based on FY2026 results. Operating losses and cash burn explain the 1-star rating, with weak cash conversion and weak capital efficiency.

Economic Dimensions

★★★★★
Effective Tax Rate: -0.14% (Tax Credit)

Quantitative Style Profile

★★★★★
POCI has a liquid, relatively low-volatility profile. Weak momentum is the primary drawback, while valuation that is moderately attractive rather than deeply discounted.

Style Classification

Quality Focused

Low VolatilitySmall / Mid Cap RiskHighly Liquid / Institution-Friendly

How Company Makes Money

Business areaWhat it includesRetail investor read
Medical OpticsCustom manufacturing of micro-optics and endoscope components for medical device OEMs.The company generates revenue by building the tiny, high-precision lenses needed for advanced surgical tools.
Defense & IndustrialDesign and production of specialized imaging systems for industrial and defense sectors.They also leverage their optical technology to serve military and industrial customers requiring custom imaging hardware.

Analyzing Revenue: Products, Geography and Growth

Revenue by Products

Product revenue - Year on Year

Valuation

Trailing PE -
Forward PE -
Enterprise Value 51.72M
Price to Sales(TTM) 1.82
Enterprise Value 51.72M
Price to Sales(TTM) 1.82
Enterprise Value to Revenue 1.64
Enterprise Value to EBITDA 129.55
Shares Outstanding 10.99M
Shares Floating 8.26M
Shares Outstanding 10.99M
Shares Floating 8.26M
Percent Insiders 19.57
Percent Institutions 39.84

Financial Metrics

🧭 Investment Snapshot

Total Revenue (Scale)

Information icon Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.

Net Income (Profit)

Information icon Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.

Free Cash Flow (Cash Strength)

Information icon Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.

📈 Growth & Strength

Operating Income (Core Profit)

Information icon Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.

EBITDA (Cash Earnings)

Information icon Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.

Gross Profit (Unit Profitability)

Information icon Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.

🛡️ Financial Safety

Cash (Liquidity Buffer)

Information icon Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.

Total Debt (Leverage Risk)

Information icon Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.

Net Working Capital (Short-Term Health)

Information icon Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.

🧱 Balance Sheet Strength

Stockholder Equity (Net Worth)

Information icon Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.

Total Assets (Asset Base)

Information icon The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.

Income Before Tax (Pre-Tax Earnings)

Information icon Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.

⚙️ Cost & Drag Factors

Cost of Revenue (Production Cost)

Information icon Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.

Total Operating Expenses (Operating Cost)

Information icon Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.

Income Tax Expense (Tax Drag)

Information icon Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Form CRS provides a relationship summary of our automated advisory services, flat subscription fees, and conflicts of interest. Form ADV Part 2A brochure contains complete details on services, billing, and disclosures. If any summary differs from our current regulatory filings, the filed Form ADV controls.